TransCode Therapeutics Gets Orphan Designation Status On Dextran-Coated, Nanoparticle-Conjugated Stabilized Synthetic Antisense Oligonucleotide Targeting miR-10b For The Treatment Of Pancreatic Cancer
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=926622